Expert Interview
Discussing the focal segmental glomerulosclerosis (FSGS) treatment landscape with a focus on Travere's sparsentan and competing therapies
Ticker(s): TVTXInstitution: NYU
- Director of Division of Nephrology, Norman S. Wikler Professor of Medicine & Professor of Pharmacology at NYU Langone.
- In practice for 33 years, double board certified in Nephrology and Internal Medicine, and has extensive experience treating patients with CKD and FSGS.
- Published a number of articles in peer reviewed journals and member of several professional organizations including The American Society for Clinical Investigation
How many FSGS patients do you treat?
Added By: wilson_adminWhat do you think about the data shown so far from sparsentan?
Added By: wilson_adminHow enthusiastic are you about the potential use of sparsentan as a therapy for FSGS?
Added By: wilson_adminAre You Interested In These Questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
